Molecular dynamics simulation study reveals polar nature of pathogenic mutations responsible for stabilizing active conformation of kinase domain in leucine-rich repeat kinase II

被引:0
作者
Sagar S. Bhayye
K. Roy
A. Saha
机构
[1] University of Calcutta,Department of Chemical Technology
[2] Jadavpur University,Department of Pharmaceutical Technology
来源
Structural Chemistry | 2018年 / 29卷
关键词
Parkinson’s disease; DYG loop; Kinase domain; LRRK2; MM-GBSA; Molecular dynamics;
D O I
暂无
中图分类号
学科分类号
摘要
The kinase domain of LRRK2 is increasingly gaining attention as a promising therapeutic target due to pathogenic mutation leading to development of Parkinson’s disease. Mutation in G2019S and I2020T increases the kinase activity, while A2016T mutation causes drug resistance. Increased kinase activity of LRRK2 has been associated with deposition of tau and α-synuclein proteins. However, mechanism responsible for increase in activity due to mutation is not known. In the present study, extensive molecular dynamics study has been performed on both wild and mutant homology models of DYG-In (active) conformation of the kinase domain of LRRK2 in the absence/presence of ATP at the active site to study the behavior of DYG loop. In absence of ATP, it is observed that G2019S and I2020T mutants stabilize DYG loop by increasing formation of hydrogen bond with neighboring residues, mainly with GLU 1920 and ILE 1991, respectively. In ATP-kinase complex, DYG loop also increases hydrogen bonding with neighboring residues in mutant LRRK2. The study indicates that polar side chain of mutated residues increases the polarity of DYG loop, causing an increase in hydrogen bonding with neighboring residues to stabilize the active conformation of kinase domain in LRRK2. The binding free energy of ATP is found to be higher in mutated kinase as compared to wild, due to more stable kinase domain.
引用
收藏
页码:657 / 666
页数:9
相关论文
共 132 条
[1]  
Gandhi PN(2009)Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson’s disease J Neurosci Res 87 1283-1295
[2]  
Chen SG(2014)Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies J Neurosci 34 418-433
[3]  
Wilson-Delfosse AL(2010)LRRK2 and Parkinson disease Arch Neurol 67 542-547
[4]  
Skibinski G(2014)Structural and functional in silico analysis of LRRK2 missense substitutions Mol Biol Rep 41 2529-2542
[5]  
Nakamura K(2012)Leucine-rich repeat kinase 2 inhibitors: a patent review (2006–2011) Expert Opin Ther Pat 22 1415-1426
[6]  
Cookson MR(2012)Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson’s disease Trends Pharmacol Sci 33 365-373
[7]  
Finkbeiner S(2012)Mechanisms of LRRK2-mediated neurodegeneration Curr Neurol Neurosci Rep 12 251-260
[8]  
Dächsel JC(2015)Structural characterization of LRRK2 inhibitors J Med Chem 58 3751-3756
[9]  
Farrer MJ(2010)The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease Nat Rev Neurosci 11 791-797
[10]  
Cardona F(2009)The R1441C mutation alters the folding properties of the ROC domain of LRRK2 Biochim Biophys Acta 1792 1194-1197